Investegate |Junshi Biosciences Announcements | Junshi Biosciences: Junshi Biosciences Announces Acceptance by NMPA of Investigational New Drug Application for the Subcutaneous Injection of Anti-BLyS Monoclonal Antibody

Investegate announcements from Junshi Biosciences, Junshi Biosciences Announces Acceptance by NMPA of Investigational New Drug Application for the Subcutaneous Injection of Anti-BLyS Monoclonal Antibody

Related Keywords

Guangzhou ,Guangdong ,China ,Beijing ,Maryland ,United States ,Shanghai ,Suzhou ,Jiangsu ,San Francisco ,California ,Chinese ,Junshi Biosciences ,Zhi Li ,Eli Lilly ,Institute Of Microbiology Chinese Academy Science ,Ir Team ,Journal Of Arthritis Research Treatment ,National Medical Products Administration ,Pr Team ,Junshi Biosciences Announces Acceptance ,Investigational New Drug Application ,Subcutaneous Injection ,Systemic Lupus Erythematosus ,Arthritis Research ,Microbiology Chinese Academy ,Emergency Use Authorization ,Investegate Announcements ,Investegate Company Announcements ,Lobenewswire ,Lobenewswire And Globenewswire ,Nw ,